Figure 6.
(a) A. Schematic illustration of the synthesis of DOX-ICG@LDH-PEG-B3int NPs. B. Cartoon representation of how DOX-ICG@LDH-PEG-B3int NPs remain in the tumor site through the targeting effect. C. The release of DOX and ICG from the DOX-ICG@LDH-PEG-B3int NPs in the tumor microenvironment. (b) The images of tumors isolated after treatment for 14 d (I: Saline; II: ICG@LDH-PEG-B3int+NIR; III: Free DOX; IV: DOX@LDH-PEG; V: DOX@LDH-PEG-B3int; VI: DOX-ICG@LDH-PEG-B3int+NIR). (c) B16 tumor growth curves of different groups after intravenous injection of the formulations. (d) Body weight changes over the 14 d of the experiments. (e) Kaplan–Meier survival curves (n = 3). (Reprinted with permission from Ref. [72], Copyright 2021, Elsevier).